Tiziana Life Sciences plc Banner Image

Tiziana Life Sciences plc has reached its limit for free report views

Work for Tiziana Life Sciences plc? Upgrade Your Profile and unlock all your annual reports.

Tiziana Life Sciences plc

  • Ticker TLSA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Tiziana Life Sciences plc Logo Image
  • 1-10 Employees
  • Based in London, England
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's Disease and nasally administeredMore foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
Tiziana Life Sciences plc

Most Recent Annual Report

Tiziana Life Sciences plc MOST RECENT 2020 Annual Report

Report Locked. Tiziana Life Sciences plc has reached its limit for free report views.

Older/Archived Annual Reports